168 related articles for article (PubMed ID: 10454206)
1. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.
Sausville EA; Zaharevitz D; Gussio R; Meijer L; Louarn-Leost M; Kunick C; Schultz R; Lahusen T; Headlee D; Stinson S; Arbuck SG; Senderowicz A
Pharmacol Ther; 1999; 82(2-3):285-92. PubMed ID: 10454206
[TBL] [Abstract][Full Text] [Related]
2. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
Zaharevitz DW; Gussio R; Leost M; Senderowicz AM; Lahusen T; Kunick C; Meijer L; Sausville EA
Cancer Res; 1999 Jun; 59(11):2566-9. PubMed ID: 10363974
[TBL] [Abstract][Full Text] [Related]
3. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.
Sausville EA
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):47-56. PubMed ID: 12678914
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Senderowicz AM
Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
[TBL] [Abstract][Full Text] [Related]
6. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
Grant S; Roberts JD
Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical development of cyclin-dependent kinase modulators.
Senderowicz AM; Sausville EA
J Natl Cancer Inst; 2000 Mar; 92(5):376-87. PubMed ID: 10699068
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
Roskoski R
Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
[TBL] [Abstract][Full Text] [Related]
11. Early development of cyclin dependent kinase modulators.
Roy KK; Sausville EA
Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
[TBL] [Abstract][Full Text] [Related]
12. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
Senderowicz AM
Cancer Biol Ther; 2003; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
[TBL] [Abstract][Full Text] [Related]
13. CDK inhibitors in cancer therapy: what is next?
Malumbres M; Pevarello P; Barbacid M; Bischoff JR
Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule cyclin-dependent kinase modulators.
Senderowicz AM
Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
[TBL] [Abstract][Full Text] [Related]
15. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Senderowicz AM
Leukemia; 2001 Jan; 15(1):1-9. PubMed ID: 11243375
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
Fischer PM; Lane DP
Curr Med Chem; 2000 Dec; 7(12):1213-45. PubMed ID: 11032968
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CDKs as a therapeutic modality.
Sausville EA; Johnson J; Alley M; Zaharevitz D; Senderowicz AM
Ann N Y Acad Sci; 2000 Jun; 910():207-21; discussion 221-2. PubMed ID: 10911915
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase inhibitors for treating cancer.
Toogood PL
Med Res Rev; 2001 Nov; 21(6):487-98. PubMed ID: 11607930
[TBL] [Abstract][Full Text] [Related]
19. Anticancer therapeutic strategies based on CDK inhibitors.
Esposito L; Indovina P; Magnotti F; Conti D; Giordano A
Curr Pharm Des; 2013; 19(30):5327-32. PubMed ID: 23394082
[TBL] [Abstract][Full Text] [Related]
20. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
